Survey of Cannabis Use in Patients With Chronic Inflammatory Arthritis

Brief Title

Survey of Cannabis Use in Patients With Chronic Inflammatory Arthritis

Official Title

Survey of Cannabis Use in Patients With Chronic Inflammatory Arthritis

Brief Summary

      Patients with inflammatory rheumatism very often have residual pain that is not easily
      relieved by conventional treatments. They can then use non-drug methods, such as
      physiotherapy, hypnosis or even cannabis.

      The aim of this study is to assess the percentage of patients who use cannabis to better
      relieve their pain or anxiety in chronic inflammatory rheumatism.
    

Detailed Description

      Thanks to a better understanding of the pathophysiological mechanisms of inflammatory
      rheumatism, rheumatology has known for several decades a growth in its therapeutic arsenal
      (csDMARDs, bDMARDs, tDMARDs). rheumatism control has thus been optimized.

      however, patients very often keep pain, anxiety, residual fatigue, poorly controlled by our
      conventional therapies. patients then turn to non-drug therapies, among which the use of
      cannabis.

      endocannabinoids have an analgesic and anti-inflammatory action recognized in pre-clinical
      trials. however, investigators currently lack the data to authorize its use in clinical
      rheumatology.

      the aim of this study is to determine the prevalence of cannabis users in patients with
      rheumatoid arthritis, ankylosing spondyloarthritis or psoriatic arthritis in our unit. as a
      second intention, investigators will refine the consumption characteristics. Investigators
      will also look for possible risk factors for consumption (sensitivity to pain, catastrophism,
      standard of living, anxiety, depression, rheumatic activity and quality of life).
    


Study Type

Observational


Primary Outcome

prevalence of cannabis use in patients with chronic inflammatory rheumatic conditions

Secondary Outcome

 Percentage of patients with problematic cannabis use

Condition

Rheumatoid Arthritis

Intervention

Cannabis questionnaire


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Behavioral

Estimated Enrollment

501

Start Date

May 19, 2020

Completion Date

March 19, 2021

Primary Completion Date

March 19, 2021

Eligibility Criteria

        Inclusion Criteria:

          -  Rheumatoid Arthritis (ACR 2010 Criteria)

          -  Ankylosing Spondylitis (New york or ASAS criteria)

          -  Psoriatic Arthritis (CASPAR criteria)

        Exclusion Criteria:

          -  Patient unable to complete questionnaires or unable to express informed consent

          -  Guardianship, trusteeship, deprivation of liberties, safeguard of justice
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Sylvain Mathieu, , 

Location Countries

France

Location Countries

France

Administrative Informations


NCT ID

NCT04402554

Organization ID

RNI 2020 MATHIEU

Secondary IDs

2020-A00473-36

Responsible Party

Sponsor

Study Sponsor

University Hospital, Clermont-Ferrand


Study Sponsor

Sylvain Mathieu, Principal Investigator, University Hospital, Clermont-Ferrand


Verification Date

June 2021